Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	329.04	27.71	47.28
Short-Term Investments	-	-	40.8
Cash & Cash Equivalents	329.04	27.71	88.08
Cash Growth	-	-68.54%	-
Receivables	-	-	0.26
Other Current Assets	3.03	1.65	3.87
Total Current Assets	332.07	29.36	92.21
Property, Plant & Equipment	-	6.72	8.86
Goodwill and Intangibles	-	39.36	44.06
Other Long-Term Assets	-	5.39	4.12
Total Long-Term Assets	-	51.46	57.05
Total Assets	-	80.82	149.25
Accounts Payable	-	17.27	9.51
Current Debt	-	20.89	9.38
Other Current Liabilities	54.24	18.63	13.52
Total Current Liabilities	54.24	56.79	32.41
Long-Term Debt	-	37.81	56.82
Other Long-Term Liabilities	-	2.74	3.58
Total Long-Term Liabilities	-	40.55	60.4
Total Liabilities	-	97.34	92.81
Total Debt	53.36	58.7	66.2
Debt Growth	-	-11.33%	-
Retained Earnings	-	-541.5	-395.62
Comprehensive Income	-	-	0.02
Shareholders' Equity	-570.32	-526.5	-383.94
Net Cash (Debt)	275.68	-30.99	21.88
Working Capital	277.83	-27.43	59.8

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).